HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Giuliano Maggi Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maggi, G. Articles by Ruffini, E. Search for Related Content PubMed PubMed Citation Articles by Maggi, G. Articles by Ruffini, E. Related Collections Pleura

Eur J Cardiothorac Surg 2001;19:346-350
© 2001 Elsevier Science NL

Trimodality management of malignant pleural mesothelioma

Department of Thoracic Surgery, University of Torino, San Giovanni Battista Hospital, via Genova 3, 10126 Torino, Italy

Received 9 October 2000; received in revised form 10 January 2001; accepted 13 January 2001.

Corresponding author. Tel.: +39-11-633-6635/55; fax: +39-11-696-0170
e-mail: giuliano.maggi{at}unito.it

Objective: We reviewed our experience with trimodality management of malignant pleural mesothelioma (MPM). Methods: From September 1998 to August 2000, 32 consecutive patients with histological diagnosis of MPM underwent trimodality therapy, including surgery followed by adjuvant chemotherapy and radiation therapy. Surgery consisted of pleurectomy/decortication (P/D) or pleural-pericardial-pneumonectomy and diaphragm (PPPD). Pre-operative staging according to the Brigham Staging System was accomplished using computed tomography (CT) and magnetic resonance imaging (MRI); patients with evident extrapleural spread were excluded. Results. Our series included 21 men and 11 women with a median age of 53.5 years (range 40–69). Histologically, there were 26 epithelial, four mixed and two sarcomatous MPM. Post-surgical staging was as follows: six patients were at Stage I; of these, two received a P/D and four a PPPD. Ten patients were at Stage II and all received a PPPD; 16 patients were at Stage III (under-staged pre-operatively): of these, nine patients presented extrapleural lymph node metastases (N2) and all received a PPPD, seven patients presented with chest wall or mediastinal invasion (T4) with macroscopic residual tumour, and all received a de-bulking P/D. We observed major complications in ten patients: six bleeding, two respiratory insufficiency and two nerve paralysis. There were two perioperative deaths (6.25% mortality). Twenty-seven patients out of 30 surviving surgery had a follow-up greater than 6 months; 21 patients out of 27 are alive with a median follow-up of 12.5 months. Conclusions: (1) Trimodality therapy is feasible in selected patients with MPM and has an acceptable operative mortality rate. (2) Our current pre-operative staging based on CT/MRI looks rather inaccurate and needs to be improved. (3) The high rate of post-surgical N2 patients or with diffusion to the inferior surface of the diaphragm may suggest the use of routine mediastinoscopy and laparoscopy for a more appropriate patient selection.

Key Words: Malignant pleural mesothelioma • Pleural disease • Extrapleural pneumonectomy • Pleurectomy/decortication

This article has been cited by other articles:

				G. Buduhan, S. Menon, R. Aye, B. Louie, V. Mehta, and E. Vallieres Trimodality therapy for malignant pleural mesothelioma. Ann. Thorac. Surg., September 1, 2009; 88(3): 870 - 875. [Abstract] [Full Text] [PDF]

				E. Pompeo, L. Albonici, E. Doldo, A. Orlandi, V. Manzari, A. Modesti, and T. C. Mineo Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. Ann. Thorac. Surg., August 1, 2009; 88(2): 426 - 431. [Abstract] [Full Text] [PDF]

				A. Nakas, D. S. Trousse, A. E. Martin-Ucar, and D. A. Waller Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy Eur. J. Cardiothorac. Surg., October 1, 2008; 34(4): 886 - 891. [Abstract] [Full Text] [PDF]

				A. R. M. Abdel Rahman, R. M. Gaafar, H. A. Baki, H. M. El Hosieny, F. Aboulkasem, E. G. Farahat, A. M. Nouh, and K. A. Mansour Prevalence and Pattern of Lymph Node Metastasis in Malignant Pleural Mesothelioma Ann. Thorac. Surg., August 1, 2008; 86(2): 391 - 395. [Abstract] [Full Text] [PDF]

				T. C. Mineo, V. Ambrogi, E. Pompeo, A. Baldi, F. Stella, P. Aurea, and M. Marino The Value of Occult Disease in Resection Margin and Lymph Node After Extrapleural Pneumonectomy for Malignant Mesothelioma Ann. Thorac. Surg., May 1, 2008; 85(5): 1740 - 1746. [Abstract] [Full Text] [PDF]

				British Thoracic Society Standards of Care Committ BTS statement on malignant mesothelioma in the UK, 2007 Thorax, November 1, 2007; 62(Suppl_2): ii1 - ii19. [Full Text] [PDF]

				W Weder, R. Stahel, J Bernhard, S Bodis, P Vogt, P Ballabeni, D Lardinois, D Betticher, R Schmid, R Stupp, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma Ann. Onc., July 1, 2007; 18(7): 1196 - 1202. [Abstract] [Full Text] [PDF]

				G. L. Ceresoli, C. Gridelli, and A. Santoro Multidisciplinary Treatment of Malignant Pleural Mesothelioma Oncologist, July 1, 2007; 12(7): 850 - 863. [Abstract] [Full Text] [PDF]

				J. G. Edwards, D.J. Stewart, A. Martin-Ucar, S. Muller, C. Richards, and D. A. Waller The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 981 - 987. [Abstract] [Full Text] [PDF]

				Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 697 - 703.e3.

				T. Treasure, C. Tan, L. Lang-Lazdunski, and D. Waller The MARS trial: mesothelioma and radical surgery Interactive CardioVascular and Thoracic Surgery, February 1, 2006; 5(1): 58 - 59. [Abstract] [Full Text] [PDF]

				S. Neragi-Miandoab Multimodality approach in management of malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., January 1, 2006; 29(1): 14 - 19. [Abstract] [Full Text] [PDF]

				W. Weder, P. Kestenholz, C. Taverna, S. Bodis, D. Lardinois, M. Jerman, and R. A. Stahel Neoadjuvant Chemotherapy Followed by Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma J. Clin. Oncol., September 1, 2004; 22(17): 3451 - 3457. [Abstract] [Full Text] [PDF]

				D. J. Stewart, A. Martin-Ucar, J. E. Pilling, J. G. Edwards, K. J. O'Byrne, and D. A. Waller The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma Ann. Thorac. Surg., July 1, 2004; 78(1): 245 - 252. [Abstract] [Full Text] [PDF]

				J.E. Pilling, D.J. Stewart, A.E. Martin-Ucar, S. Muller, K.J. O'Byrne, and D.A. Waller The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., April 1, 2004; 25(4): 497 - 501. [Abstract] [Full Text] [PDF]

				W.J. de Vries and M.A. Long Treatment of mesothelioma in Bloemfontein, South Africa Eur. J. Cardiothorac. Surg., September 1, 2003; 24(3): 434 - 440. [Abstract] [Full Text] [PDF]